Carry On Cosentyx As Novartis Lines Up More Blockbusters

The Swiss giant has posted a strong set of results with the company highly confident that its flagship immune drug can keep the competition at bay.

Novartis
CEO Narasimhan gives his end-of-year report • Source: Novartis

Novartis AG is aiming to launch 10 potential blockbusters by 2020 but for the moment, the Swiss major is reaping the benefits from an established big seller – Cosentyx (secukinumab) – which is continuing to grow at an impressive rate.

Speaking at Novartis' annual press conference in Basel on Jan. 30, chief executive Vas Narasimhan highlighted how much of a...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Earnings

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.